Antiepileptic Medications for the Treatment of Epilepsy

 

 Buy Article Permissions and Reprints

ABSTRACT

Epilepsy is one of the most common neurological conditions encountered worldwide. The development of newer antiepileptic drugs (AEDs) has expanded over recent years, and the use of such drugs for indications other than epilepsy has also broadened. These factors insure that the majority of health care providers will be using an increasing number of AEDs in the care of their patients. Contained herein is a review of the mechanism of action of AEDs, individual drugs and their potential drug interactions, and general principles to guide the clinician in selection, implementation, and long-term monitoring of AEDs.

REFERENCES

• 1 White H S, Woodhead J H, Wilcox K S, Stables J P, Kupferberg H J, Wolf H H. Discovery and preclinical development of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs 5th ed. Philadelphia: Lippincott Williams & Wilkins 2001 0: 36-48
  Google Scholar
• 2 French J A, Dichter M A. New antiepileptic drug development: medical perspective. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs 5th ed. Philadelphia: Lippincott Williams & Wilkins 2001 0: 49-57
  Google Scholar
• 3 Cramer J A, Fisher R, Menachem E B. New antiepileptic drugs: comparison of key clinical trials.  Epilepsia . 1999;  40 590-600
  CrossrefPubMedGoogle Scholar
• 4 Cereghino J J, Mitchell W G, Murphy J. Treating repetitive seizures with a rectal diazepam formulation.  Neurology . 1998;  51 1274-1282
  CrossrefPubMedGoogle Scholar
• 5 French J, Smith M, Faught E, Brown L. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy.  Neurology . 1999;  52 1540-1545
  CrossrefPubMedGoogle Scholar
• 6 US Gabapentin Study Group Number 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study.  Neurology . 1993;  43 2292-2298
  PubMedGoogle Scholar
• 7 Chadwick D W, Anhut H, Greiner M J. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures.  Neurology . 1998;  51 1282-1288
  CrossrefPubMedGoogle Scholar
• 8 Matsuo F, Bergen D, Faught E. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0.5 Clinical Trial Group.  Neurology . 1993;  43 2284-2291
  PubMedGoogle Scholar
• 9 Dren A T, Moore E L, and the US Lamictal Protocol 0.5 Clinical Trial Group. Placebo-controlled, dose response evaluation of the efficacy and safety of lamotrigine as add-on therapy in epileptic outpatients with partial seizures.  Epilepsia . 1993;  32 (suppl 3) 20
  PubMedGoogle Scholar
• 10 Loiseau P, Yuen A WC, Douche B, Menageer T, Arne-Bes M C. A randomized double-blind placebo-controlled cross-over add-on trial of LAMICTAL in patients with treatment-resistant partial seizures.  Epilepsy Res . 1990;  7 136-145
  CrossrefPubMedGoogle Scholar
• 11 Ramaratnam S, Marson A G, Baker G A. Lamotrigine add-on for drug-resistant partial epilepsy.  Cochrane Database Syst Rev . 2000;  (3) CD001909
  PubMedGoogle Scholar
• 12 Frank L M, Enlow T, Holmes G L. Lamictal (lamotrigine) monotherapy for typical absence seizures in children.  Epilepsia . 1999;  40 357-359
  PubMedGoogle Scholar
• 13 Steiner T J, Dellaportas C I, Findley L J. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin.  Epilepsia . 1999;  40 601-607
  CrossrefPubMedGoogle Scholar
• 14 Motte J, Trevathan E, Arvidsson J F, Barrera M N, Mullens E L, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.  N Engl J Med . 1998;  339 851-852
  CrossrefPubMedGoogle Scholar
• 15 Guberman A H, Besag F, Brodie M. Lamotrigine-associated rash: risk/benefit considerations in adults and children.  Epilepsia . 1999;  40 985-991
  CrossrefPubMedGoogle Scholar
• 16 Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel AED levetiracetam (ucbL059) in the kindling model of temporal lobe epilepsy.  J Pharmacol Exp Ther . 1998;  284 474-479
  PubMedGoogle Scholar
• 17 Cereghino J J, Biton V, Abou-Khalil B, Dreifuss F, Gauer L J, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial.  Neurology . 2000;  55 236-242
  PubMedGoogle Scholar
• 18 Shorvon S D, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind randomized, placebo controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures.  Epilepsia . 2000;  41 1179-1186
  PubMedGoogle Scholar
• 19 Patsalos P N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics.  Pharmacol Ther . 2000;  85 77-85
  CrossrefPubMedGoogle Scholar
• 20 Barcs G, Walker E B, Elger C E. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy.  Epilepsia . 2000;  41 1597-1607
  CrossrefPubMedGoogle Scholar
• 21 Glauser T A, Nigro M, Sachdeo R. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group.  Neurology . 2000;  54 2237-2244
  CrossrefPubMedGoogle Scholar
• 22 Schachter S C, Vazquez B, Fisher R S. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures.  Neurology . 1999;  52 732-737
  PubMedGoogle Scholar
• 23 Richens A, Chadwick D W, Duncan J S. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial.  Epilepsy Res . 1995;  21 37-42
  CrossrefPubMedGoogle Scholar
• 24 Sachdeo R C, Leroy R F, Krauss G L. Tiagabine therapy for complex partial seizures: a dose-frequency study.  Arch Neurol . 1997;  54 595-601
  PubMedGoogle Scholar
• 25 Uthman B M, Rowan A J, Ahmann P A. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial.  Arch Neurol . 1998;  55 56-62
  CrossrefPubMedGoogle Scholar
• 26 Biton V, Montouris G D, Ritter F. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures.  Neurology . 1999;  52 1330-1337
  PubMedGoogle Scholar
• 27 Abou-Khalil B. Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group.  Epilepsia . 2000;  41 (suppl 1) 72-76
  PubMedGoogle Scholar
• 28 Ritter F, Glauser  T A, Elterman R D, Wyllie E. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures.  Epilepsia . 2000;  41 (suppl 1) 82-85
  CrossrefPubMedGoogle Scholar
• 29 Jette N J, Marson A G, Kadir Z A, Hutton J L. Topiramate for drug resistant epilepsy.  Cochrane Database Syst Rev . 2000;  (2) CD001417
  PubMedGoogle Scholar
• 30 Glauser T A, Levisohn P M, Ritter F, Sachdeo R C. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group.  Epilepsia . 2000;  41 (suppl 1) 86-90
  CrossrefPubMedGoogle Scholar
• 31 Chadwick D W, Marson A G. Zonisamide for drug-resistant partial epilepsy.  Cochrane Database Syst Rev . 2000;  (2) CD001416
  PubMedGoogle Scholar
• 32 Oommen K J, Mathews S. Zonisamide: a new antiepileptic drug.  Clin Neuropharmacol . 1999;  22 192-200
  PubMedGoogle Scholar
• 33 Semah F, Picot M C, Adam C. Is the underlying cause of epilepsy a major prognostic factor for recurrence?.  Neurology . 1998;  51 1256-1262
  CrossrefPubMedGoogle Scholar
• 34 Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: a guideline for discontinuing antiepileptic drugs in seizure-free patients (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology . 1996;  47 600-602
  PubMedGoogle Scholar
• 35 Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission.  Lancet . 1991;  337 1175-1180
  PubMedGoogle Scholar
• 36 Kwan P, Brodie M J. Effectiveness of first antiepileptic drug.  Epilepsia . 2001;  42 1255-1260
  CrossrefPubMedGoogle Scholar
• 37 Kwan P, Brodie M J. Early identification of refractory epilepsy.  N Engl J Med . 2000;  342 314-319
  CrossrefPubMedGoogle Scholar
• 38 Dlugos D J, Sammel M D, Strom B L, Farrar J T. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy.  Neurology . 2001;  57 2259-2264
  PubMedGoogle Scholar
• 39 Karceski S, Morrell M, Carpenter D. The Expert Consensus Guideline Series: the treatment of epilepsy.  Epilepsy Beh . 2001;  2 A1-A50
  PubMedGoogle Scholar
• 40 Holmes L B, Harvey E A, Coull B A. The teratogenicity of AED drugs.  N Engl J Med . 2001;  344 1132-1138
  CrossrefPubMedGoogle Scholar
• 41 Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology . 1998;  51 944-948
  PubMedGoogle Scholar
• 42 Zahn C A, Morrell M J, Collins S D, Labiner D M, Yerby M S. Management issues for women with epilepsy: a review of the literature. American Academy of Neurology Practice Guidelines.  Neurology . 1998;  51 949-956
  PubMedGoogle Scholar
• 43 Yerby M S, Annegers J F, Bruni J. A North American registry for epilepsy and pregnancy: a unique public/private partnership of health surveillance.  Epilepsia . 1998;  39 793-798
  PubMedGoogle Scholar